Vivimed Labs gets zero US FDA observations, stock surges by 6.5%

Vivimed Labs on Tuesday informed the BSE that its API manufacturing facility in Sant Celoni, Spain was recently inspected by the US FDA. It has been granted zero 483 observations by the regulator.

The company has delivered over 35% returns in a year’s time. It has outperformed the BSE Healthcare and underperformed and BSE small-cap over the same period.

Meanwhile, Vivimed Labs was up by 6.5% at Rs 111.90 per share at 10:09 hours IST on BSE. It hit a high of Rs 113.90 and a low of Rs 109.25 during morning hours.

Vivimed Labs Limited is a pharmaceutical and chemical products company. The healthcare vertical of the company is engaged in the custom manufacturing engagements for active pharmaceutical ingredients (APIs) and formulations for generics-manufacturing companies.

Stock View :-

Vivimed Labs Ltd is currently trading at Rs 112, up by Rs 6.95 or 6.62% from its previous closing of Rs 105.05 on the BSE.

The scrip opened at Rs 109.9 and has touched a high and low of Rs 113.9 and Rs 109.25 respectively. So far 1753376(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 861.27 crore.

The BSE group 'B' stock of face value Rs 2 has touched a 52 week high of Rs 136.4 on 20-Apr-2017 and a 52 week low of Rs 68 on 09-Aug-2016. Last one week high and low of the scrip stood at Rs 115 and Rs 104.6 respectively.

The promoters holding in the company stood at 36.48 % while Institutions and Non-Institutions held 4.68 % and 58.85 % respectively.
The stock is currently trading above its 50 DMA.

Vivimed Labs Ltd :-
BSE 112.00 6.95 (6.62%)
NSE 111.90 6.95 (6.62%)


Comments

Popular posts from this blog

Top intraday trading ideas for afternoon trade for Monday 31 December 2018

WELCOME TO SMART MONEY FINANCIAL SERVICES

F&O: Put writing at all immediate strikes shows Nifty may hold up